Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22 11:06 ET

The net profit of Harbin Pharmaceutical Co., Ltd. has more than tripled in the three quarters: driven by the recovery of health products, sustainability is yet to be tested

Back to normal

wallstreetcnOct 29, 2023 22:18 ET

Tailong Pharmaceutical Co., Ltd. plans to welcome the new owner, Zhengzhou high-tech production investment is planned to become the actual controller.

On September 23rd, Capital State learned that the controlling shareholder of A-share company Tai long Pharmaceutical (600222.SH) signed the "share transfer Framework Agreement". As of the date of this announcement, Zhengzhou Zhongsheng Industrial Group Co., Ltd. (hereinafter referred to as "Zhongsheng Industry"), the company's controlling shareholder, holds 132 million shares of the company, accounting for 23.08% of the company's total share capital, all of which are tradable shares with unlimited sales conditions. Zhongsheng Industries has pledged a total of 50 million shares of the company, accounting for 37.75% of the shares held and 8.71% of the total share capital of the company. The above-mentioned stock pledge is not expected to pose an obstacle to the progress of the transaction.

資本邦Sep 22, 2021 23:54 ET

From the chairman to the wanted criminal! Qiu Qiang, former chairman of Zhongjiang Trust and Guosheng Securities, is wanted.

If the most distressing thing in life is, it must be a sudden fall from the peak, being pulled out of all halos and titles, from heaven to hell overnight. And Qiu Qiang, there must be such pain and helplessness, this once controlled Zhongjiang Trust and Guosheng Securities, suspected of money laundering and gambling crimes, from the chairman to a wanted criminal. From the chairman of the board to the wanted criminal on July 16, the Jiangxi Provincial Public Security Bureau began to investigate Qiu Qiang's suspected money laundering and gambling crimes on December 13, 2018, according to the wanted information posted on the official website of the Changsha Public Security Bureau. Qiu Qiang, the main suspect in the case, is suspected of money laundering and gambling.

證券之星Jul 23, 2021 02:41 ET

The variety structure has improved significantly, and Harbin Pharmaceutical shares are expected to reverse losses in the first half of the year compared

On July 16, Capital Bang learned that A-share listed company Harbin Pharmaceutical shares (code: 600664.SH) issued a semi-annual report performance notice, the company is expected to reverse losses from January to June 2021, the net profit belonging to the shareholders of the listed company is 291 million to 349 million yuan, the net profit increased by 187.36% to 204.84% compared with the same period last year, and the company belongs to the chemical pharmaceutical industry. The company made the above forecast based on the following reasons: 1. During the reporting period, the company focused on target management, continuously improved the professional ability of the team by subdividing the business team and related treatment areas, and sold the industrial part of the company compared with the same period last year.

資本邦Jul 18, 2021 22:54 ET